Sun Pharma eyes mid-high single digit revenue growth in FY26, bets on innovation

Sun Pharmaceutical Industries targets mid- to high-single digit topline growth in FY26, focusing on innovative medicines and increased R&D investment.

Leave a Reply

Your email address will not be published. Required fields are marked *